

Ivone Gomes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/197719/publications.pdf>

Version: 2024-02-01

44
papers

2,872
citations

257450

24
h-index

289244

40
g-index

45
all docs

45
docs citations

45
times ranked

3287
citing authors

#	ARTICLE	IF	CITATIONS
1	A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5135-5139.	7.1	377
2	μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neurogenesis. British Journal of Pharmacology, 2006, 148, 387-395.	5.4	274
3	G Protein-Coupled Receptor Heteromers. Annual Review of Pharmacology and Toxicology, 2016, 56, 403-425.	9.4	222
4	Increased Abundance of Opioid Receptor Heteromers After Chronic Morphine Administration. Science Signaling, 2010, 3, ra54.	3.6	191
5	Novel endogenous peptide agonists of cannabinoid receptors. FASEB Journal, 2009, 23, 3020-3029.	0.5	135
6	Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cellular Signalling, 2005, 17, 549-557.	3.6	124
7	Cannabinoid Receptor-induced Neurite Outgrowth Is Mediated by Rap1 Activation through $G_{\alpha i}$ -triggered Proteasomal Degradation of Rap1GAP1. Journal of Biological Chemistry, 2005, 280, 11413-11421.	3.4	118
8	Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Molecular Brain Research, 2005, 138, 228-235.	2.3	118
9	Identification of a μ - δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12072-12077.	7.1	114
10	Hemoglobin-derived Peptides as Novel Type of Bioactive Signaling Molecules. AAPS Journal, 2010, 12, 658-669.	4.4	102
11	Conformation State-sensitive Antibodies to G-protein-coupled Receptors*. Journal of Biological Chemistry, 2007, 282, 5116-5124.	3.4	94
12	Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions. Molecular Pharmacology, 2020, 98, 96-108.	2.3	85
13	Biased signaling by endogenous opioid peptides. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11820-11828.	7.1	78
14	G Protein-Coupled Receptor Heteromerization: A Role in Allosteric Modulation of Ligand Binding. Molecular Pharmacology, 2011, 79, 1044-1052.	2.3	75
15	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochemical Pharmacology, 2014, 92, 448-456.	4.4	73
16	Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology, 2014, 86, 228-240.	4.1	69
17	GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16211-16216.	7.1	67
18	Identification of GPR83 as the receptor for the neuroendocrine peptide PEN. Science Signaling, 2016, 9, ra43.	3.6	66

#	ARTICLE	IF	CITATIONS
19	Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay. <i>Current Protocols in Pharmacology</i> , 2016, 75, 2.16.1-2.16.31.	4.0	47
20	INTERACTIONS BETWEEN delta OPIOID RECEPTORS AND alpha2A-ADRENOCEPTORS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2004, 31, 833-836.	1.9	37
21	Opioid Receptor Oligomerization: Detection and Functional Characterization of Interacting Receptors. , 2003, 84, 157-184.		36
22	Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects. <i>British Journal of Pharmacology</i> , 2022, 179, 1544-1564.	5.4	35
23	Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 219-229.	4.9	32
24	Collybolide is a novel biased agonist of μ -opioid receptors with potent antipruritic activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6041-6046.	7.1	29
25	Disease-Specific Heteromerization of G-Protein-Coupled Receptors That Target Drugs of Abuse. <i>Progress in Molecular Biology and Translational Science</i> , 2013, 117, 207-265.	1.7	28
26	Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake. <i>Science Signaling</i> , 2016, 9, ra55.	3.6	26
27	The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. <i>Neuropsychopharmacology</i> , 2017, 42, 2527-2536.	5.4	23
28	Synthesis and Pharmacology of a Novel μ -Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13618-13637.	6.4	22
29	Post-activation-mediated Changes in Opioid Receptors Detected by N-terminal Antibodies. <i>Journal of Biological Chemistry</i> , 2008, 283, 10735-10744.	3.4	20
30	A novel peptide that improves metabolic parameters without adverse central nervous system effects. <i>Scientific Reports</i> , 2017, 7, 14781.	3.3	19
31	Regulation of an Opioid Receptor Chaperone Protein, RTP4, by Morphine. <i>Molecular Pharmacology</i> , 2019, 95, 11-19.	2.3	18
32	Compartment-specific opioid receptor signaling is selectively modulated by different dynorphin peptides. <i>ELife</i> , 2021, 10, .	6.0	17
33	Hemopressin as a breakthrough for the cannabinoid field. <i>Neuropharmacology</i> , 2021, 183, 108406.	4.1	15
34	Neuropeptide PEN and Its Receptor GPR83: Distribution, Signaling, and Regulation. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1884-1891.	3.5	13
35	GPR83 Engages Endogenous Peptides from Two Distinct Precursors to Elicit Differential Signaling. <i>Molecular Pharmacology</i> , 2022, 102, 29-38.	2.3	13
36	G-Protein-Coupled Heteromers. <i>Methods in Enzymology</i> , 2013, 521, 219-238.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Regulation of Opioid Receptors by Their Endogenous Opioid Peptides. Cellular and Molecular Neurobiology, 2021, 41, 1103-1118.	3.3	12
38	Opioid-Induced Signaling and Antinociception Are Modulated by the Recently Deorphanized Receptor, GPR171. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 56-62.	2.5	11
39	Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states. PLoS ONE, 2017, 12, e0187306.	2.5	10
40	Autoantibodies Blocking M_3 Muscarinic Receptors Cause Postganglionic Cholinergic Dysautonomia. Annals of Neurology, 2020, 88, 1237-1243.	5.3	8
41	High-throughput screening and validation of antibodies against synaptic proteins to explore opioid signaling dynamics. Communications Biology, 2021, 4, 238.	4.4	5
42	GPR171, a Newly Deorphanized Hypothalamic G Protein-Coupled Receptor is Involved in the Regulation of Reward-Related Behaviors. FASEB Journal, 2015, 29, 1019.1.	0.5	0
43	Identification of small molecule ligands targeting GPR83, a G-protein coupled receptor activated by the abundant neuropeptide PEN. FASEB Journal, 2018, 32, 829.9.	0.5	0
44	The Neuropeptide Receptor System, BigLEN-GPR171, Interacts with the Opioid System to Relieve Pain. FASEB Journal, 2018, 32, 684.12.	0.5	0